Implementation of Pharmacogenetic Testing in Hospital Wards

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate whether it is feasible to implement pharmacogenetic testing as part of medication review while the patient is admitted to hospital.

Detailed Description
-----------------
Earlier studies have shown that pharmacogenetic testing may contribute to optimizing the efficacy of medication treatment and to reduce the risk of adverse effects. Inclusion of pharmacogenetic testing as part of medication reviews reveals more serious drug related problems and leads to more changes in medication treatment than medication review alone. The use of pharmacogenetic testing as part of medication reviews has not earlier been systematically investigated in hospital patients in Norway. There is little documentation of what is needed to implement the use of pharmacogenetic testing in a hospital ward. The investigators are conducting a descriptive study in two internal medicine wards at Akershus University Hospital. 50 patients using minimum 5 regular drugs including at least one relevant for pharmacogenetic testing will be enrolled in the study.

Official Title
-----------------
Implementation of Pharmacogenetic Testing as Part of Medication Reviews in Hospital Wards

Conditions
-----------------
Admitted Multimorbid Patients

Intervention / Treatment
-----------------
* Genetic: Pharmacogenetic test
* Other: Medication review


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: at least 2 long-term conditions at least 5 regular drugs of which at least one relevant for pharmacogenetic testing at least 2 years life expectancy able to communicate in Norwegian able to give informed consent summary care record Exclusion Criteria: moderate to severe dementia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Pharmacogenetic test<br>Medication review including results from pharmacogenetic testing | Genetic: Pharmacogenetic test<br>* genotyping for genes that affect drug metabolism<br>Other: Medication review<br>* systematic and interdisciplinary method aiming to increase quality of medication treatment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with results from pharmacogenetic testing included in medication review | Number of patients | from admission to discharge, an average of 1 week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Acceptance of recommendations | Degree of acceptance of recommendations after pharmacogenetic testing, by prescribers | after medication review and before discharge, an average of 3 days | 
| Documentation of information from pharmacogenetic testing | Number of patients with information from pharmacogenetic testing documented in the patient journal | after medication review and before discharge, an average of 3 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pharmacogenetics, implementation, medication review